MacroGenics, Inc. is a leading biotechnology company in the United States specializing in pharmaceuticals. With an ESG score of 26.7, it is considered to be a medium-risk investment. The company is dedicated to discovering and developing antibody-based therapeutics for cancer treatment. Their flagship product, MARGENZA, is designed for adult patients with metastatic HER2-positive breast cancer. MacroGenics also has a robust pipeline of innovative product candidates targeting tumor-associated antigens and immune checkpoint molecules, such as MGC018, Lorigerlimab, Tebotelimab, and more.